DE4130918A1 - Alpha-sympatholytic and beta-sympathomimetic contg. solns. - for injection after dental anaesthesia to relieve vasoconstriction and reduce anaesthetic effect - Google Patents
Alpha-sympatholytic and beta-sympathomimetic contg. solns. - for injection after dental anaesthesia to relieve vasoconstriction and reduce anaesthetic effectInfo
- Publication number
- DE4130918A1 DE4130918A1 DE19914130918 DE4130918A DE4130918A1 DE 4130918 A1 DE4130918 A1 DE 4130918A1 DE 19914130918 DE19914130918 DE 19914130918 DE 4130918 A DE4130918 A DE 4130918A DE 4130918 A1 DE4130918 A1 DE 4130918A1
- Authority
- DE
- Germany
- Prior art keywords
- beta
- alpha
- sympatholytic
- sympathomimetic
- solution according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Die Erfindung betrifft Arzneimittel zur Unterbrechung der lokalen Anästhesie, insbesondere nach zahnärzt licher Behandlung sowie deren Verwendung.The invention relates to pharmaceuticals for interruption of local anesthesia, especially after dentist Licher treatment and their use.
Bei zahnärztlichen Eingriffen wie dem Zementieren einer Krone oder eines Inlays, dem Legen einer Füllung oder ähnlichen Behandlungsmaßnahmen ist eine Lokal anästhesie im Kieferbereich von Vorteil, da sie dem Patienten während der Behandlung Schmerzen nimmt und dem behandelnden Arzt eine störungsfreie Behandlung ermöglicht.For dental procedures such as cementing a crown or an inlay, laying a filling or similar treatments is a local Anesthesia in the jaw area of advantage, since they are the Patients taking pain during treatment and the treating doctor a trouble-free treatment allows.
So vorteilhaft eine Lokalanästhesie während der Behand lung auch ist, so ist sie für den Patienten nach der Behandlung häufig mit einer langandauernden mimischen und sprachlichen Beeinträchtigung verbunden.So beneficial a local anesthetic during the treatment mentation, it is after the patient Treatment often with a long-lasting mimic and linguistic impairment.
Bei den meisten in der Zahnheilkunde gebräuchlichen Lokalanästhetika sorgen Adrenalin oder verwandte Sub stanzen für eine mehr oder weniger starke vasokonstrik torische Wirkung im Bereich der Einstichstelle, wodurch eine relative Anämie im Operationsgebiet erzeugt wird, so daß das eigentliche Anästhetikum in diesem Bereich eine lange Verweildauer hat.Used by most in dentistry Local anesthetics provide adrenaline or related sub punching for a more or less strong vasoconstrict toric effect in the area of the puncture site, causing a relative anemia in the operating area is generated so that the actual anesthetic in this area has a long residence time.
Der Erfindung liegt die Aufgabe zugrunde, die vasokon striktorische Wirkung im Operationsgebiet nach Ab schluß der Behandlung so schnell wie möglich aufzu heben. The invention is based on the object vasokon striktorische effect in the operation area after Ab conclusion of the treatment as soon as possible to lift.
Diese Aufgabe wird durch die Injektionslösung nach Anspruch 1 gelöst.This task is followed by the injection solution Claim 1 solved.
Die Wirkung basiert auf der gesteigerten Durchblutung des Behandlungsgebietes, so daß die Verweildauer des Lokalanästhetikums verringert und die Anästhesie aufgehoben wird.The effect is based on the increased blood flow of the treatment area, so that the residence time of Local anesthetic decreases and anesthesia will be annulled.
Besonders geeignete alpha-Sympatholytika sind sogenan nte alpha1-Sympatholytika wie Urapidil, die auch als pharmazeutisch verträgliche Säureadditionssalze ein gesetzt werden können.Particularly suitable alpha-sympatholytic agents are so-called alpha 1 -sympatholytics, such as urapidil, which can also be used as pharmaceutically acceptable acid addition salts.
Besonders geeignete beta-Sympathomimetika sind soge nannte beta2-Sympathomimetika wie Salbutamol, Terbu talin, Fenoterol, Clenbuterol, Bamethan, Buphenin und Isoxsuprin.Particularly suitable beta-sympathomimetics are so-called beta 2 -sympathomimetics such as salbutamol, terbu talin, fenoterol, clenbuterol, bamethane, buphenin and isoxsuprin.
Die Herstellung der erfindungsgemäßen Injektions mittel erfolgt nach den in den Arzneibüchern festge legten Regeln. Ein geeignetes Lösungsmittel ist beispielsweise physiologische Kochsalzlösung. Zur Verbesserung der Löslichkeit kommen Zusätze von Ethanol, Glycerol, 1,2-Propylenglykol oder Poly ethylenglykolen in Betracht.The preparation of the injection according to the invention The medium is determined by the pharmacopoeias set rules. A suitable solvent is for example, physiological saline. to Solubility enhancements come from additives Ethanol, glycerol, 1,2-propylene glycol or poly ethylene glycols into consideration.
Als besonders geeignet zur Beendigung der Anästhesie erwies sich eine Injektionslösung aus Isoxsuprinhydro chlorid und Urapidil. Dabei sind etwa 10 mg Isoxsuprin hydrochlorid und 21,8 mg Urapidilhydrochlorid in 6 ml eines Gemisch aus physiologischer Kochsalzlösung und Propylenglykol gelöst.Especially suitable for stopping anesthesia proved an injection solution of Isoxsuprinhydro chloride and urapidil. This is about 10 mg isoxsuprin hydrochloride and 21.8 mg urapidil hydrochloride in 6 ml a mixture of physiological saline and Dissolved in propylene glycol.
Geeignete Zubereitungen sind:Suitable preparations are:
In den erfindungsgemäßen Injektionslösungen beträgt das Gewichtsverhältnis alpha-Sympatholytikum zu beta- Sympathomimetikum ungefähr 0,5 bis 1,5 zu 2. Bei etwa 90% der Patienten zeigt sich nach Injektion von 1 bis 2 ml der erfindungsgemäßen Lösungen pro Zahn eine Aufhebung der Lokalanästhesie innerhalb weniger Minuten.In the injection solutions according to the invention the weight ratio alpha sympatholytic to beta Sympathomimetic about 0.5 to 1.5 to 2. At about 90% of patients appear after injection of 1 to 2 ml of the solutions according to the invention per tooth Cancellation of local anesthesia within less Minutes.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19914130918 DE4130918A1 (en) | 1991-09-17 | 1991-09-17 | Alpha-sympatholytic and beta-sympathomimetic contg. solns. - for injection after dental anaesthesia to relieve vasoconstriction and reduce anaesthetic effect |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19914130918 DE4130918A1 (en) | 1991-09-17 | 1991-09-17 | Alpha-sympatholytic and beta-sympathomimetic contg. solns. - for injection after dental anaesthesia to relieve vasoconstriction and reduce anaesthetic effect |
Publications (1)
Publication Number | Publication Date |
---|---|
DE4130918A1 true DE4130918A1 (en) | 1993-03-18 |
Family
ID=6440807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19914130918 Withdrawn DE4130918A1 (en) | 1991-09-17 | 1991-09-17 | Alpha-sympatholytic and beta-sympathomimetic contg. solns. - for injection after dental anaesthesia to relieve vasoconstriction and reduce anaesthetic effect |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE4130918A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004072016A1 (en) * | 2003-02-14 | 2004-08-26 | Kissei Pharmaceutical Co., Ltd. | Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof |
CN101200451B (en) * | 2006-12-15 | 2010-12-15 | 重庆药友制药有限责任公司 | Method for preparing hydrochloride urapidil |
CN104173281A (en) * | 2014-09-05 | 2014-12-03 | 河北一品制药有限公司 | Urapidil hydrochloride injection and preparation method thereof |
-
1991
- 1991-09-17 DE DE19914130918 patent/DE4130918A1/en not_active Withdrawn
Non-Patent Citations (2)
Title |
---|
1979,Vol.90, Ref.16458c * |
Chem.Abstr.: 1992,Vol.116,Ref.143858k * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004072016A1 (en) * | 2003-02-14 | 2004-08-26 | Kissei Pharmaceutical Co., Ltd. | Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof |
JPWO2004072016A1 (en) * | 2003-02-14 | 2006-06-01 | キッセイ薬品工業株式会社 | Aminoalcohol derivatives, pharmaceutical compositions containing them, and uses thereof |
US7423185B2 (en) | 2003-02-14 | 2008-09-09 | Kissei Pharmaceutical Co., Ltd. | Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof |
US7674938B2 (en) | 2003-02-14 | 2010-03-09 | Kissei Pharmaceutical Co., Ltd. | Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof |
JP4567596B2 (en) * | 2003-02-14 | 2010-10-20 | キッセイ薬品工業株式会社 | Aminoalcohol derivatives, pharmaceutical compositions containing them, and uses thereof |
CN101200451B (en) * | 2006-12-15 | 2010-12-15 | 重庆药友制药有限责任公司 | Method for preparing hydrochloride urapidil |
CN104173281A (en) * | 2014-09-05 | 2014-12-03 | 河北一品制药有限公司 | Urapidil hydrochloride injection and preparation method thereof |
CN104173281B (en) * | 2014-09-05 | 2017-01-11 | 河北一品制药有限公司 | Urapidil hydrochloride injection and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60126265T2 (en) | Composition consisting of phentolamine mesylate and their use | |
Reves et al. | Comparison of two benzodiazepines for anaesthesia induction: midazolam and diazepam | |
DE60012745T2 (en) | NEW USES OF COMPOUNDS AS ANTIBACTERIAL AGENTS | |
DE69402330T2 (en) | ANALGETIC AGENT AND THEIR USE | |
Anker‐Møller et al. | Continuous blockade of the lumbar plexus after knee surgery: a comparison of the plasma concentrations and analgesic effect of bupivacaine 0.250% and 0.125% | |
DE69529156T2 (en) | USE OF AMINO-HYDROGENATED CHINAZOLINE COMPOUNDS AND THEIR DERIVATIVES FOR BODYING IN DRUG ADDICTION | |
Dittmann et al. | Spinal anaesthesia with 29 gauge Quincke point needles and post dural puncture headache in 2,378 patients | |
DE68913907T2 (en) | Method of treating interstitial cystitis. | |
Robertson et al. | Evaluation of doxapram for arousal from general anaesthesia in outpatients | |
DE69605531T2 (en) | Carnitine derivative as a medicine for the treatment of arteriosclerosis obliterans | |
EP1103256A1 (en) | Use of ketamine for the treatment of neuroendocrine immune dysfunction und algogenic psychosyndrome | |
Vloka et al. | Combined popliteal and posterior cutaneous nerve of the thigh blocks for short saphenous vein stripping in outpatients: an alternative to spinal anesthesia | |
Stephens et al. | Intravenous sedation for handicapped dental patients: a clinical trial of midazolam and propofol | |
JPH01503146A (en) | Methods of treating body tissue and administering medicines to body tissue | |
EP1978995A1 (en) | Method for the treatment and/or prophylaxis of multiple sclerosis, and use of erythropoietin for the manufacture of a medicament for the intermittent treatment and/or intermittent prophylaxis of multiple sclerosis | |
DE69431986T2 (en) | USE OF GRANISETRON TO TREAT POST-OPERATIVE Nausea AND Vomiting | |
Marais et al. | Throat pain and pharyngeal packing: a controlled randomized double‐blind comparison between gauze and tampons | |
DE4130918A1 (en) | Alpha-sympatholytic and beta-sympathomimetic contg. solns. - for injection after dental anaesthesia to relieve vasoconstriction and reduce anaesthetic effect | |
DE10045845A1 (en) | Xenon as a medicine | |
DE69529819T2 (en) | NEW COMBINATION OF A BETABLOCKER WITH A LOCAL ANESTHETIC | |
Casati et al. | A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia | |
DE60133284T2 (en) | MEDICAL COMBINATION PREPARATION FOR THE TREATMENT OF INJURED ABNORMAL TISSUE | |
Neill | Postoperative analgesia following brachial plexus block | |
Van den Berg | Comparison of ondansetron and prochlorperazine for the prevention of nausea and vomiting after adenotonsillectomy. | |
Rood et al. | Clinical experience with 5 per cent lignocaine solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OM8 | Search report available as to paragraph 43 lit. 1 sentence 1 patent law | ||
8139 | Disposal/non-payment of the annual fee |